GU Cancers 2026 | KIM-1 levels in papillary renal cell carcinoma from the CALYPSO trial

So as part of an exploratory analysis of the Calypso trial, we measured KIM1 levels in the papillary cohort. In total, we enrolled 41 patients in the papillary cohort and out of them we had available samples in 31. Those 31 patients we had available samples at baseline, that means time zero before starting treatment. And then we also have sequential samples in 19 patients. Those sequential samples were taken at a median of eight weeks after starting treatment. And the treatment was, in this papillary cohort, it was with Durvalumab, which is an immune checkpoint inhibitor, and Savolitinib, which is a MET inhibitor. So what we did was we wanted to see whether KIM1 levels were raised in papillary cancer as it is raised in advanced clear-cell carcinoma. And we confirmed that indeed in papillary renal cell we can see high KIM1 expression in patients with advanced kidney cancer. We showed that the median levels in papillary were significantly raised compared to clear cell. It was around 7,800. That was the median level in the baseline samples compared to 5,000 in clear cell. And that difference was statistically significant. We also showed that among patients who had a radiological response, KIM1 at baseline was significantly lower. So those are the main findings in our poster. We acknowledged that our sample might be small because we only have like 31 at baseline and 19 with treatment but we think even though it’s small it’s still important data because this particular population has not been quite studied as of yet.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.